Sprint Bioscience EBITDA vs. Price To Book
| SPRINT Stock | SEK 1.57 0.05 3.09% |
For Sprint Bioscience profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sprint Bioscience to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sprint Bioscience AB utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sprint Bioscience's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sprint Bioscience AB over time as well as its relative position and ranking within its peers.
Sprint |
Sprint Bioscience Price To Book vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Sprint Bioscience's current stock value. Our valuation model uses many indicators to compare Sprint Bioscience value to that of its competitors to determine the firm's financial worth. Sprint Bioscience AB is currently regarded as top stock in ebitda category among its peers. It also is currently regarded as top stock in price to book category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Sprint Bioscience by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Sprint Bioscience's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Sprint Price To Book vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Sprint Bioscience |
| = | (24.22 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Sprint Bioscience |
| = | 2.61 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Sprint Price To Book Comparison
Sprint Bioscience is currently under evaluation in price to book category among its peers.
Sprint Bioscience Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Sprint Bioscience, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sprint Bioscience will eventually generate negative long term returns. The profitability progress is the general direction of Sprint Bioscience's change in net profit over the period of time. It can combine multiple indicators of Sprint Bioscience, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Sprint Bioscience AB develops pharmaceutical products in the areas of cancer and metabolism. Sprint Bioscience AB was founded in 2009 and is based in Huddinge, Sweden. Sprint Bioscience operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange.
Sprint Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Sprint Bioscience. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sprint Bioscience position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sprint Bioscience's important profitability drivers and their relationship over time.
Use Sprint Bioscience in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sprint Bioscience position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sprint Bioscience will appreciate offsetting losses from the drop in the long position's value.Sprint Bioscience Pair Trading
Sprint Bioscience AB Pair Trading Analysis
The ability to find closely correlated positions to Sprint Bioscience could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sprint Bioscience when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sprint Bioscience - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sprint Bioscience AB to buy it.
The correlation of Sprint Bioscience is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sprint Bioscience moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sprint Bioscience moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sprint Bioscience can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Sprint Bioscience position
In addition to having Sprint Bioscience in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Long Short Funds Thematic Idea Now
Long Short Funds
Funds or Etfs that are designed to hedge away market risk by investing in combination of bonds, stocks, derivative instruments as well as short positions to maximize returns irrespective of market conditions. The Long Short Funds theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Long Short Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Sprint Stock
To fully project Sprint Bioscience's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sprint Bioscience at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sprint Bioscience's income statement, its balance sheet, and the statement of cash flows.